Junlin Ho Biography and Net Worth

General Counsel & Corporate Secretary of Scholar Rock

Junlin Ho joined Scholar Rock in 2018 and has served as General Counsel & Corporate Secretary since February 2021, overseeing all legal affairs, including corporate governance, compliance, and intellectual property. She has over 15 years of experience leading and advising life sciences companies on various legal aspects associated with corporate governance, business development, financing, securities law, commercial product planning and launches, and international operations. Prior to Scholar Rock, she served as Associate General Counsel at Foundation Medicine where she helped lead the team in support of that company’s initial public offering and was a member of the team that negotiated a major strategic partnership. Additionally, Junlin served as Associate General Counsel, Corporate at Ziopharm Oncology and was a corporate attorney in the life sciences practice at the law firm Ropes & Gray LLP. She received her J.D. from the University of Chicago Law School and a B.S. from the Massachusetts Institute of Technology.

What is Junlin Ho's net worth?: The estimated net worth of Junlin Ho is at least $11.38 million as of February 17th, 2026. Ms. Ho owns 241,545 shares of Scholar Rock stock worth more than $11,384,016 as of May 5th. This net worth estimate does not reflect any other investments that Ms. Ho may own. Learn More about Junlin Ho's net worth.
How do I contact Junlin Ho?: The corporate mailing address for Ms. Ho and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Junlin Ho's contact information.
Has Junlin Ho been buying or selling shares of Scholar Rock?: Junlin Ho has not been actively trading shares of Scholar Rock during the past quarter. Most recently, Junlin Ho sold 9,580 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a transaction totalling $445,757.40. Following the completion of the sale, the general counsel now directly owns 241,545 shares of the company's stock, valued at $11,239,088.85. Learn More on Junlin Ho's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), David Hallal (CEO), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), Vikas Sinha (CFO), Akshay Vaishnaw (President, R&D), Keith Woods (COO), and Keith Woods (COO). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, Scholar Rock insiders bought shares 3 times. They purchased a total of 530,038 shares worth more than $19,988,928.11. In the last year, insiders at the sold shares 33 times. They sold a total of 509,614 shares worth more than $21,862,372.68. The most recent insider tranaction occured on April, 16th when COO Keith Woods sold 10,220 shares worth more than $506,605.40. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 4/16/2026.

Junlin Ho Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/17/2026	Sell	9,580	$46.53	$445,757.40	241,545
1/16/2026	Sell	8,016	$44.48	$356,551.68	214,553
2/18/2025	Sell	5,742	$36.83	$211,477.86	189,295
1/16/2025	Sell	9,039	$44.20	$399,523.80	195,037
6/17/2024	Sell	4,695	$8.98	$42,161.10	204,076
2/16/2024	Sell	3,489	$15.74	$54,916.86	208,771

Junlin Ho Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $47.13

$45.54

$47.96

50 Day Range

MA: $46.16

$39.79

$50.01

2 Week Range

Now: $47.13

$27.07

$51.63

Volume

583,550 shs

Average Volume

1,388,516 shs

Market Capitalization

$5.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7